The fact that PPARγ1 was shown to be expressed in inflammatory cells and that there was a group of available synthetic agonists of PPARγ that were approved as drugs (for the treatment of type 2 diabetes) raised the appealing prospect that the same drugs could easily be used to modulate inflammation as well. Here, PPARG is linked to type 2 diabetes mellitus.